The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply reports and data to the agency during the approved clinical trials rather than at completion. The agency said it had already completed two proof-of-concept trials using RTCT reporting. As part of the announcement, the FDA issued a request for information on a proposed pilot program to assess AI’s impact on efficiency, speed and quality of decision-making in early phase clinical trials. The agency will accept comments, submitted through regulations.gov, for 30 days following publication in the Federal Register.

Headline
The White House issued an executive order June 2 on cybersecurity efforts regarding artificial intelligence. The order instructs federal…
Headline
Daniel Daly, Ph.D., executive director of the Center for Theology and Ethics in Catholic Health at the Catholic Health Association, explores the ethical future…
Headline
The AHA wrapped up its inaugural Healthier Together Conference in Dallas May 14 with a plenary session on how the application of artificial intelligence-driven…
Headline
The Medicaid and CHIP Payment and Access Commission approved recommendations it will issue to Congress in its June report on oversight and increased…
Headline
John Riggi, AHA national advisor for cybersecurity and risk, will moderate a webinar May 5 at 1 p.m. ET that will explore how bad actors are leveraging…
Headline
The Cybersecurity and Infrastructure Security Agency, National Security Agency and international partners have released guidance on adopting agentic artificial…